Beyond glycemic control, Semaglutide has shown remarkable cardiovascular benefits. In the SUSTAIN-6 trial, semaglutide demonstrated a significant reduction in major adverse cardiovascular events, including cardiovascular death, non-fatal myocardial infarction, and stroke when compared to placebo. This finding highlights the potential of semaglutide to provide comprehensive cardiovascular protection in patients with type 2 diabetes.
Obesity is a common comorbidity in patients with type 2 diabetes and can exacerbate glycemic control. Semaglutide offers an additional benefit of promoting weight loss. The STEP program, a series of trials evaluating semaglutide for obesity treatment, demonstrated substantial weight loss in participants. In the STEP 1 trial, patients treated with semaglutide achieved an average weight loss of 14.9%, surpassing the weight loss achieved with other anti-obesity medications. This dual effect of semaglutide on glycemic control and weight management is particularly advantageous for patients with type 2 diabetes.
Read More- https://cmiblogdailydose.blogspot.com/2023/05/semaglutide-controls-level-of-blood.html
